Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest bladder cancer clinical trials programs in the United States. A team of urologic surgeons, medical oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people with bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, robotic-assisted surgery, and blue light cystoscopy to detect and remove early stage bladder cancer.

Clinical Trials and Research Studies

Phase 3

A Phase 3 Randomized Double-Blind Clinical Study of Pembrolizumab +Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum

Learn More

Phase 1

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Learn More

Phase 3

A Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Learn More

Phase 1

A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Learn More